Brief: Jeune Aesthetics Doses First Subject In Phase 1 Study Of Kb301 For Improvement Of Lateral Canthal Lines At Rest
18/04/2023 12:05
April 18 (Reuters) - Krystal Biotech Inc KRYS.O :
* JEUNE AESTHETICS ANNOUNCES DOSING OF FIRST SUBJECT IN
PHASE 1,
COHORT 3 STUDY OF KB301 FOR THE IMPROVEMENT OF LATERAL CANTHAL
LINES AT REST
Source text for Eikon: ID:nGNX9j5L5g
Further company coverage: KRYS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Krystal Biotech
See all newsBrief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion